Source-grounded facts extracted from Cabaletta Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cabaletta Bio, Inc.: Increased authorized shares of common stock from 300,000,000 to 600,000,000 (effective 2026-06-09).
“On June 9, 2026, the Company filed a Certificate of Amendment to the Company’s Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective on filing.”
Cabaletta Bio, Inc. shareholders approved Adjournment proposal to permit further solicitation if needed for Charter Amendment Proposal at the 2026-06-09 meeting.
“Although Proposal 6 was deemed not necessary because there was a quorum present and there were sufficient proxies at the time of the Annual Meeting to approve the Charter Amendment Proposal, it was approved by the requisite vote as follows”
Cabaletta Bio, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-06-09 meeting.
“The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 5.”
Cabaletta Bio, Inc. shareholders approved Amendment to Third Amended and Restated Certificate of Incorporation to increase authorized shares of common stock from 300,000,000 to 600,000,000 at the 2026-06-09 meeting.
“The Company’s stockholders approved the amendment to the Company's Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 600,000,000, recommended for approval as Proposal 4 at the Annual Meeting.”
Cabaletta Bio, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended for ratification in Proposal 2 at the Annual Meeting.”
Cabaletta Bio, Inc. shareholders approved Election of two Class I directors, Scott Brun, M.D. and Shawn Tomasello, MBA at the 2026-06-09 meeting.
“The Company’s stockholders approved the Class I director nominees, Scott Brun, M.D. and Shawn Tomasello, MBA, recommended for election in Proposal 1 at the Annual Meeting.”
Cabaletta Bio, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 14, 2026, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026.”
Cabaletta Bio, Inc. reported preliminary financial results for the three months ended March 31, 2026.
“As of March 31, 2026, the Company had approximately $117 million in cash and cash equivalents. This preliminary financial information is subject to completion, and is the responsibility of management and has been prepared in good faith on a consistent basis with prior periods. However, the Company has not reported its financial results for the three months ended March 31, 2026, and its actual results could be materially different from this preliminary financial information.”
Cabaletta Bio, Inc. entered into Underwriting Agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. valued at $2.90 per share (effective 2026-05-04).
“On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).”
Cabaletta Bio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 23, 2026, Cabaletta Bio, Inc. (the "Company") announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.”
Cabaletta Bio, Inc.: Increased number of authorized shares of common stock from 150,000,000 to 300,000,000 (effective 2025-06-09).
“On June 9, 2025, the Company filed a Certificate of Amendment to the Company’s Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective on filing.”
Cabaletta Bio, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
“Cabaletta Bio, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.”
Cabaletta Bio, Inc. reported financial results for third quarter ended September 30, 2023.
“On November 9, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2023.”
Cabaletta Bio, Inc. reported financial results for second quarter ended June 30, 2023.
“On August 10, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2023.”
Shawn Tomasello was appointed as Director at Cabaletta Bio, Inc..
“On July 21, 2023, upon the recommendation of its Nominating and Corporate Governance Committee (the “NCG Committee”), the Board of Directors (the “Board”) of Cabaletta Bio, Inc. (the “Company”) appointed Shawn Tomasello to join the Board, effective as of July 21, 2023 (the “Effective Date”), to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from five (5) to six (6) directors.”
Cabaletta Bio, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-01 meeting.
“The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 27,268,632 5,343 9,170 0”
Cabaletta Bio, Inc. shareholders approved Approval of amendment to the 2019 Plan at the 2023-06-01 meeting.
“The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 21,684,293 3,045,532 12,925 2,540,395”
Cabaletta Bio, Inc. shareholders approved Election of Class I director Scott Brun, M.D. at the 2023-06-01 meeting.
“The votes cast at the Annual Meeting were as follows: For Withheld Broker Non-Votes Scott Brun, M.D. 23,574,643 1,168,107 2,540,395”
Cabaletta Bio, Inc. entered into Underwriting Agreement with Cowen and Company, LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC valued at 7,250,000 shares of common stock at $12.00 per share, option for additional 1,087,500 shares (effective 2023-05-17).
“On May 17, 2023, Cabaletta Bio, Inc. (the “Company” or “Cabaletta”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC (collectively, the “Underwriters”), related to a public offering (the “Offering”) of 7,250,000 shares of common stock of the Company, par value $0.00001 per share (the “Common Stock”) at a price to the public of $12.00 per share.”
Cabaletta Bio, Inc. reported financial results for first quarter ended March 31, 2023.
“On May 11, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2023.”
Cabaletta Bio, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.
“On March 16, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.